News & Analysis on Clinical Trial Services & Contract Research And Development
Preclinical results show promise for Tyra Bioscience’s lead drug candidate for the treatment for hypochondroplasia, a condition for which there are currently no therapeutic options available.
CatSci, a UK-based innovation partner for the development of pharmaceutical manufacturing processes, will be expanding its service offering with the acquisition of Reach Separations.
Under the terms of the agreement, Eli Lilly will obtain the exclusive rights to acquire Radionetics Oncology for $1 billion.